Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $773.06 million. The enterprise value is $795.72 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 231.46 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 231.46M |
| Shares Outstanding | 231.46M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 3.53% |
| Owned by Institutions (%) | 62.69% |
| Float | 188.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.22 |
| Forward PS | 32.76 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.28
| Current Ratio | 3.28 |
| Quick Ratio | 3.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.97 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -34.25% |
| Return on Invested Capital (ROIC) | -50.67% |
| Return on Capital Employed (ROCE) | -104.52% |
| Revenue Per Employee | $303,800 |
| Profits Per Employee | -$1.08M |
| Employee Count | 145 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.41M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +375.99% in the last 52 weeks. The beta is 1.96, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +375.99% |
| 50-Day Moving Average | 2.62 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 71.35 |
| Average Volume (20 Days) | 2,706,290 |
Short Selling Information
The latest short interest is 24.42 million, so 10.55% of the outstanding shares have been sold short.
| Short Interest | 24.42M |
| Short Previous Month | 24.92M |
| Short % of Shares Out | 10.55% |
| Short % of Float | 12.98% |
| Short Ratio (days to cover) | 8.58 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $44.05 million and -$156.16 million in losses. Loss per share was -$0.69.
| Revenue | 44.05M |
| Gross Profit | 44.05M |
| Operating Income | -153.34M |
| Pretax Income | -158.57M |
| Net Income | -156.16M |
| EBITDA | -153.22M |
| EBIT | -153.34M |
| Loss Per Share | -$0.69 |
Full Income StatementBalance Sheet
The company has $180.22 million in cash and $202.88 million in debt, giving a net cash position of -$22.65 million or -$0.10 per share.
| Cash & Cash Equivalents | 180.22M |
| Total Debt | 202.88M |
| Net Cash | -22.65M |
| Net Cash Per Share | -$0.10 |
| Equity (Book Value) | -82.33M |
| Book Value Per Share | -0.36 |
| Working Capital | 141.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$158.43 million and capital expenditures -$79,000, giving a free cash flow of -$158.51 million.
| Operating Cash Flow | -158.43M |
| Capital Expenditures | -79,000 |
| Free Cash Flow | -158.51M |
| FCF Per Share | -$0.68 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -348.10% |
| Pretax Margin | -359.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.46% |
| Shareholder Yield | -0.46% |
| Earnings Yield | -20.20% |
| FCF Yield | -20.50% |
Analyst Forecast
The average price target for Gossamer Bio is $8.60, which is 157.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.60 |
| Price Target Difference | 157.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 39.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -10.1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.1 |
| Piotroski F-Score | n/a |
